类风湿关节炎伴恶性实体瘤(文献综述)

欧美国家有很多关于类风湿关节炎(RA)肿瘤风险的大样本研究，有的认为，比总体人群相比，RA总的肿瘤风险没有增加[1-5]，有的甚至认为肿瘤风险还较低[6-7]。hakravarty等人的一项-分析发现RA患者的肿瘤风险没有增加[8]。但依然有相当数量的研究认为肿瘤风险是增加的[9-12]，Smitten等对观察性研究进行的-分析也发现RA患者的肿瘤风险增加[13]。很多研究都得出RA患者血液系统肿瘤风险增加，而结肠肿瘤风险下降的结论[1-4，9-11, 14-18]。亚洲国家中日本和韩国在2011年和2012年也先后发表了RA并肿瘤的大样

本研究结果，RA患者相较总体人群肿瘤风险没有增加[19-20]。2011年台湾地区阳明大学的Chen YJ研究发现RA患者的肿瘤风险增加，尤其是造血系统及肾肿瘤，随访时间延长，肿瘤相对风险降低[21]。2014年发表的台湾地区的Huang WK等根据台湾健保资料进行研究发现，台湾的RA患者总体肿瘤风险与总体人群相比没有显著增高，但造血系统肿瘤发病风险轻度增加，结肠肿瘤风险轻度下降[22]。A合并肿瘤的发病机制不明。疾病本身和治疗措施都有可能增加肿瘤的风险。英国的Mercer LK等发现：使用非生物DMARD治疗的RA患者的肺癌、霍奇金淋巴瘤和非霍奇金淋巴瘤风险增加，而前列腺与女性生殖道肿瘤风险降低[12]，并指出肿瘤坏死因子不增加英国RA人群肿瘤风险[23]，而荷兰的Ramiro S等进行了系统回顾，发现生物DMARDs不增加总体肿瘤风险，轻度增加黑色素瘤风险，而原有的化学药物DMARDs没有发现新的安全问题[24] 。Lopez-Olivo MA等对2012年以前的随机对照研究进行分析发现，对比一般DMARD和安慰剂，生物制剂治疗患者至少随访6个月不增加肿瘤风险[25]。Moulis G等进行-分析后也得出相同结论，推荐剂量下使用抗肿瘤坏死因子治疗RA短期内不增加肿瘤风险[26]。在亚洲人群方面，2014年发表的文献中台湾地区阳明大学医学院的Chun-Ying Wu等人研究发现抗肿瘤坏死因子治疗RA不增加肿瘤风险[27]而美国的andersen CL等发表在著名杂志PLOS ONE上的论文指出，与总体人群相比，RA患者的肿瘤风险没有增加，且与病程无关，意味着治疗措施并不增加肿瘤风险[28]。

笔者认为：RA患者免疫系统功能活跃，但其他系统却表现出功能缺陷，因此对一些治疗药物的致癌作用很敏感，持续激活的淋巴细胞最终可能转化成恶性肿瘤。当RA患者突然出现病情进展迅速且治疗效果不佳时，应警惕可能并发恶性肿瘤。

RA自身的肿瘤发病率是研究RA治疗药物致肿瘤风险的基础，英国的Mercer LK等指出判定生物制剂增加肿瘤风险时应对RA自身的肿瘤风险加以考虑[12]。不同的国家和地区，人群存在人种、卫生状况、教育程度等差异，流行病学资料可能存在差异。国内关于RA与恶性肿瘤的研究仅有少量病例报道[29，30]，尚未有大样本的调查研究。本文希望能起到抛砖引玉的作用，期待国内也能有大样本的研究获得符合我们大陆地区的数据，从而更好地指导RA的治疗与研究。

参考文献

1 Thomas E, Brewster DH, Black RJ,et al. Risk of malignancy among patients with rheumatic conditions.[J]Int J Cancer, 2000(8): 497–502.

2 Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. [J]Arthritis Rheum, 2007(56):2886–2895

3 Askling J, Fored CM, Brandt L, et al .Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. [J]Ann Rheum Dis, 2005(64): 1421–1426.

4 Franklin J, Lunt M, Bunn D, Symmons D, et al. Influence of inflammatory polyarthritis on cancer incidence and survival: results from a community--d prospective study[J]. Arthritis Rheum, 2007(56):790–798.

5 Abasolo L, Judez E, Descalzo MA, Gonzalez-Alvaro I, et al. Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a South European population. [J] Semin Arthritis Rheum, 2008 (37):388–397.

6 Cibere J, Sibley J, Haga M .et al. Rheumatoid arthritis and the risk of malignancy. [J]Arthritis Rheum, 1997(40):1580–1586

7 Gridley G, McLaughlin JK, Ekbom A, et al Incidence of cancer among patients with rheumatoid arthritis. [J]J Nat Cancer Inst, 1993 (85):307–311.

8 Chakravarty EF, Genovese MC .Associations between rheumatoid arthritis and malignancy. [J] Rheum Dis Clin North Am ,2004 (30):271–284.

9 Ekstrom K, Hjalgrim H, Brandt L, et al. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. [J]Arthritis Rheum ,2003，48(4):963–970

10 Kauppi M, Pukkala E, Isomaki H .Elevated incidence of hematologic malignancies in patients with Sjogren’s syndrome compared with patients with rheumatoid arthritis (Finland). [J] Cancer Causes Control, 1997(8):201–204.

11 Mellemkjaer L, Linet MS, Gridley G, et al. Rheumatoid arthritis and cancer risk. [J] Eur J Cancer, 1996，32A(10): 1753–1757.

12 Mercer LK, Davies R, Galloway JB, et al . Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. [J] Rheumatology (Oxford), 2013(52):91–98.

13 Smitten AL, Simon TA, Hochberg MC, et al. A - analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. [J] Arthritis Res Ther, 2008 (10):R45.

14 Symmons DP, Ahern M, Bacon PA, et al . Lymphoproliferative malignancy in rheumatoid arthritis: a study of 20 cases. [J] Ann Rheum Dis ,1984 (43):132–135.

15 Askling J, Fored CM, Baecklund E, et al .Haematopoietic malignancies in rheumatoid arthritis:lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. [J] Ann Rheum Dis ,2005 (64):1414–1420.

16 Geborek P, Bladstrom A, Turesson C, et al .Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis,but may be associated with an increased risk of lymphomas. [J] Ann Rheum Dis ,2005 (64):699–703.

17 Parikh-Patel A, White RH, Allen M, et al. Risk of cancer among rheumatoid arthritis patients in California. [J] Cancer Causes Control ,2009 (20):1001–1010.

18 Chang S, Park J, Lee Y, et al. Comparison of cancer incidence among patients with rheumatic disease: a retrospective cohort study.[J] Arthritis Res Ther, 2014，16(5):428.

19 Kim YJ, Shim JS, Choi CB,et al. Mortality and incidence of malignancy in Korean patients with rheumatoid arthritis. [J] J Rheumatol, 2012 (39):226–232.

20 Moritomo H, Ueda T, Hiyama T, et al. The risk of cancer in rheumatoid patients in Japan. [J] Scand J Rheumatol, 1995 (24): 157–159.

21 Chen YJ, Chang YT, Wang CB, et al. The risk of cancer in patients with rheumatoid arthritis: a nationwide cohort study in Taiwan. [J] Arthritis Rheum ,2011(63):352–358.

22 Huang WK, Chiou MJ, Kuo CF,et al. No overall increased risk of cancer in patients with rheumatoid arthritis: a nationwide dynamic cohort study in Taiwan.[J] Rheumatol Int, 2014，34(10): 1379-86.

23 Mercer LK, Lunt M, Low AL, et al. BSRBR Control Centre Consortium. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.[J] Ann Rheum Dis, 2014(1)：1-7.

24 Ramiro S1, Gaujoux-Viala C, Nam JL, et al.. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 UPDATE of the EULAR recommendations for management of rheumatoid arthritis. [J] Ann Rheum Dis, 2014,73(3):529-35.

25 Lopez-Olivo MA1, Tayar JH, Martinez-Lopez JA, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a --analysis.[J] JAMA, 2012，308(9): 898-908.

26 Moulis G1, Sommet A, Béné J, Montastruc F,et al. Cancer risk of anti-TNF-α at recommended doses in adult rheumatoid arthritis: a --analysis with intention to treat and per protocol analyses. [J] PLoS One, 2012，7(11):e48991.

27 Wu CY, Chen DY, Shen JL,et al.The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study[J]. Arthritis Res Ther, 2014，16(5):449.

28 andersen CL, Lindegaard H, Vestergaard H,et al. Risk of lymphoma and solid cancer among patients with rheumatoid arthritis in a primary care setting.[J] PLoS One,2014，9(6): e99388.

29 李景怡，方勇飞，王勇. 类风湿关节炎合并急性髓细胞白血病1例[J].第三军医大学学报,2002,24(11):1345.

30 叶剑，郑明英，陈浩莉，等，类风湿关节炎并白血病1例[J]. 疑难病杂志，2010(2)：148.

此文章内容仅代表医生观点，仅供参考。涉及用药、治疗等问题请到当地医院就诊，谨遵医嘱！